Motley Fool  Apr 25  Comment 
The biotech's stock took a hit due to disappointing midstage results for its experimental hepatitis C drug.
Motley Fool  Apr 24  Comment 
Despite a soaring market, these stocks fell. Find out why.
Benzinga  Feb 2  Comment 
Ladenburg Thalmann’s Christopher S. James initiated coverage of four biotech companies with a Buy rating, given that each has a promising lead drug candidate that is expected to drive growth in the near future. Achillion...
Forbes  Feb 1  Comment 
It’s becoming more and more common for senior, scientific executives to leave big drug companies either for small biotech companies or start-up initiatives.

You may also be interested in articles related to Achillion Pharmaceuticals (ACHN):


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki